<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TESTREDÂ C-III- methyltestosteroneÂ capsuleÂ </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<h1>
<span class="Bold">Testred<span class="Sup">Â®</span></span><br><span class="Bold"> C-III</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fbbf9686-af5c-4ce4-932f-e2123b902560"></a><a name="section-1"></a><p></p>
<p class="First">Brand of<br><span class="Bold">MethylTESTOSTERone</span><br><span class="Bold">Capsules USP, 10 mg</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_2c225109-f81a-454c-9bf4-cda5411be11b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are steroids that develop and maintain primary and secondary male sex characteristics.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are derivatives of cyclopentanoperhydrophenanthrene. Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are C-19 steroids with a side chain at C-17, and with two angular methyl groups. Testosterone is the primary endogenous androgen. In their active form, all drugs in the class have a 17-beta hydroxy group. 17-alpha alkylation (methylTESTOSTERone) increases the pharmacologic activity per unit weight compared to testosterone when given orally.</p>
<p>MethylTESTOSTERone, a synthetic derivative of testosterone, is an androgenic preparation given by the oral route in a capsule form. Each capsule contains 10 mg of MethylTESTOSTERone USP. It has the following structural formula:</p>
<div class="Figure">
<a name="id244"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09db5a9d-9662-4bfb-824c-9c9aaad488dc&amp;name=image-01.jpg">
</div>
<p>C<span class="Sub">20</span>H<span class="Sub">30</span>O<span class="Sub">2</span> M.W. 302.46<br>17-Î²-hydroxy-17-methylandrost-4-en-3-one</p>
<p>MethylTESTOSTERone occurs as white or creamy white crystals or powder, which is soluble in various organic solvents but is practically insoluble in water.</p>
<p>Each capsule, for oral administration, contains 10 mg of MethylTESTOSTERone. In addition, each capsule contains the following inactive ingredients: Corn starch NF, Gelatin NF, FD&amp;C Blue #1, FD&amp;C Red #40.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clin"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis, and scrotum. The development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal chord thickening, alterations in body musculature, and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, phosphorus, and decreased urinary excretion of calcium. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers. In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates, but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of growth process. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).</p>
<p>There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_3ac1870a-ae84-4a61-9671-9a1bf3b667d9"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Testosterone given orally is metabolized by the gut and 44 percent is cleared by the liver of the first pass. Oral doses as high as 400 mg per day are needed to achieve clinically effective blood levels for full replacement therapy. The synthetic androgen, methylTESTOSTERone, is less extensively metabolized by the liver and has a longer half-life. It is more suitable than testosterone for oral administration.</p>
<p>Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; and 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways. There are considerable variations of the half-life of testosterone as reported in the literature, ranging from 10 to 100 minutes.</p>
<p>In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_40960542-62c6-47e3-bd20-8d2a928b96b6"></a><a name="section-4.1"></a><p></p>
<h2>1. Males</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:</p>
<dl>
<dt>1.</dt>
<dd>Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired) â€” testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome; or orchidectomy.</dd>
<dt>2.</dt>
<dd>Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired) â€” gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.<p class="First">Safety and efficacy of Testred<span class="Sup">Â® </span>(methyltestosterone) in men with â€œage-related hypogonadismâ€? (also referred to as â€œlate-onset hypogonadismâ€?) have not been established.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may be used to stimulate puberty in carefully selected males with clearly <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. These patients usually have a familial pattern of <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see <a href="#warn">WARNINGS</a>).</p>
</dd>
<dt>3.</dt>
<dd><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may be used to stimulate puberty in carefully selected males with clearly <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. These patients usually have a familial pattern of <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see <a href="#warn">WARNINGS</a>).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1d87d938-6c15-4a9c-b89a-3295bc7045dc"></a><a name="section-4.2"></a><p></p>
<h2>2. Females</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contra"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate, and in women who are or may become pregnant. When administered to pregnant women, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus. This <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> is related to the amount of drug given and the age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester. If the patient becomes pregnant while taking these drugs, she should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with breast cancer, androgen therapy may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by stimulating <span class="product-label-link" type="condition" conceptid="78308" conceptname="Osteolysis">osteolysis</span>. In this case, the drug should be discontinued.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> has been associated with the development of <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span> including hepatocellular carcinoma. (See <a href="#p_carcino">PRECAUTIONSâ€”Carcinogenesis</a>). <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis hepatis</span> can be a life-threatening or fatal complication.</p>
<p><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occur with 17-alpha-alkylandrogens at a relatively low dose. If <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined. Drug-induced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is reversible when the medication is discontinued.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
<p>There have been postmarketing reports of venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, including <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients using testosterone products, such as methyltestosterone.  Evaluate patients who report symptoms of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, warmth and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in the lower extremity for DVT and those who present with acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> for PE.  If a venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> is suspected, discontinue treatment with methyltestosterone and initiate appropriate workup and management.</p>
<p>Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men.  To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, with the use of testosterone compared to non-use.  Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use Testred<span class="Sup">Â®</span> (methyltestosterone).</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be a serious complication in patients with preexisting cardiac, renal, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. In addition to discontinuation of the drug, diuretic therapy may be required.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> frequently develops and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.</p>
<p>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_54a66089-b46f-4944-a36e-5e0614d39bb3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_0f94a0f8-11ae-4f5c-95f3-a46e6e231a2e"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Women should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, clitoromegaly and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is necessary to prevent irreversible <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>. Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following androgen use at high doses. A decision may be made by the patient and the physician that some <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> will be tolerated during treatment for breast carcinoma.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_602616e5-e1a4-455b-ac9a-51f520cc3a9b"></a><a name="section-7.2"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First">The physician should instruct patients to report any of the following side effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<table width="90%">
<col width="28%">
<col width="5%">
<col width="58%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First">Adult or Adolescent Males:</p></td>
<td class="Toprule"></td>
<td class="Toprule"><p class="First">Too frequent or persistent erections of the penis.</p></td>
</tr>
<tr>
<td></td>
<td></td>
<td><p class="First">Any male adolescent patient receiving <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> for <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> should have bone development checked every six months.</p></td>
</tr>
<tr>
<td><p class="First">Women:</p></td>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods or more hair on the face.</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">All Patients:</p></td>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">Any <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ID_c5f427d2-b287-492d-926e-4853fb8d859c"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<dl>
<dt>1.</dt>
<dd>Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy (See <a href="#warn">WARNINGS</a>).</dd>
<dt>2.</dt>
<dd>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, liver function tests should be obtained periodically.</dd>
<dt>3.</dt>
<dd>Periodic (every 6 months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.</dd>
<dt>4.</dt>
<dd>Hemoglobin and hematocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_abcc76e9-0c3a-4253-8297-332472daa322"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Anticoagulants:</span> C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are started or stopped.</dd>
<dt>2.</dt>
<dd>
<span class="Bold">Oxyphenbutazone:</span> Concurrent administration of oxyphenbutazone and <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may result in elevated serum levels of oxyphenbutazone.</dd>
<dt>3.</dt>
<dd>
<span class="Bold">Insulin:</span> In diabetic patients the metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and insulin requirements.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="ID_51220651-cbc0-4470-8120-d29b82de95bf"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interferences</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="p_carcino"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_53319840-5d87-4dec-99b7-f3559ae6949d"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Bold">Animal Data</span></h3>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_06cdf8ba-3b2f-4f80-9c30-5cfa3d7be530"></a><a name="section-7.6.2"></a><p></p>
<h3><span class="Bold">Human Data</span></h3>
<p class="First">There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_221040f1-ac4f-458f-8ec6-cadc72eb6fd4"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_a4202d9b-380c-4667-8943-5609166edcb4"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold">Teratogenic effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16e83b6b-5295-4aa1-8f16-220b0bf7bf8b"></a><a name="section-7.7.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category X</span></h4>
<p class="First">(See <a href="#contra">CONTRAINDICATIONS</a>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_876b7f3d-3c0f-4205-bbdd-546e71c30571"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_970077b6-22cb-4c28-8342-605d71e78961"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every six months by an X-ray of hand and wrist (See <a href="#usage">INDICATIONS AND USAGE</a> and <a href="#warn">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_6753e344-217c-4326-9635-cef084d324d3"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f7cd5f2f-7308-42b9-87a8-8bce45f7d421"></a><a name="section-8.1"></a><p></p>
<h2>Endocrine and Urogenital</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_120130d2-618a-4738-80a2-ad2e9c2bab95"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Female</span></h3>
<p class="First">The most common side effects of androgen therapy are <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and other menstrual irregularities, inhibition of gonadotropin secretion and <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are discontinued. When administered to a pregnant woman <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of external genitalia of the female fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d399f39d-9bec-4212-a51b-c1d8732d10b4"></a><a name="section-8.1.2"></a><p></p>
<h3><span class="Bold">Male</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, and excessive frequency and duration of penile erections. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosages (see <a href="#clin">CLINICAL PHARMACOLOGY</a>).</p>
<p><span class="Italics">Skin and appendages:</span> <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4339092" conceptname="Male pattern alopecia">male pattern baldness</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
<p><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>:</span> Retention of sodium, chloride, water, potassium, calcium and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests, rarely hepatocellular neoplasms and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> (see <a href="#warn">WARNINGS</a>).</p>
<p><span class="Italics">Hematologic:</span> Suppression of clotting factors II, V, VII, and X, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy and <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p><span class="Italics">Nervous System:</span> Increased or decreased libido, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and generalized <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p><span class="Italics">Metabolic:</span> Increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span></p>
<p><span class="Italics">Miscellaneous:</span> Rarely <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_a0901ae5-fe9c-4314-9958-17c35bf5f967"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">MethylTESTOSTERone Capsules are classified as a schedule III Controlled Substance under the Anabolic Steroids Act of 1990.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_6b68dbee-39b0-4ba6-940a-2340cd14b34f"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of acute overdosage with the <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_019f89d9-fa7e-48c8-b5e1-3533f59a4828"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Prior to initiating Testred<span class="Sup">Â®</span> (methyltestosterone), confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that those serum testosterone concentrations are below the normal range.</p>
<p>MethylTESTOSTERone capsules are administered orally. The suggested dosage for <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions.</p>
<p>Replacement therapy in androgen-deficient males is 10 to 50 mg of methylTESTOSTERone daily. Various dosage regimens have been used to induce pubertal changes in hypogonadal males, some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration both in determining the initial dose and in adjusting the dose.</p>
<p>Doses used in <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> generally are in the lower range of that given above, and for a limited duration, for example 4 to 6 months.</p>
<p>Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease. Thus, many experts prefer to use the shorter acting androgen preparations rather than those with prolonged activity for treating breast carcinoma, particularly during the early stages of androgen therapy. The dosage of methylTESTOSTERone for androgen therapy in breast carcinoma in females is from 50-200 mg daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_0a9ceeca-1db0-47cf-8f44-dd88eee0a197"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MethylTESTOSTERone capsules USP 10 mg are red capsules imprinted "VRX 0901" on both sections. They are available in bottles of 100.</p>
<p>NDC 0187-0901-01</p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_40740988-7c74-49a1-b719-4dbb58627f95"></a><a name="section-12.1"></a><p></p>
<p class="First">Store at 25Â°C (77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1797fa08-62d8-4c07-91ee-924a139222ff"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Manufactured for: </span></p>
<p>Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807 USA</p>
<p><span class="Bold">By:</span><br>Valeant Canada LP</p>
<p>1956 Bourdon Street</p>
<p>Montreal, Quebec, H4M 1V1</p>
<p><br>Made in Canada</p>
<p>9410201<br>Revision 04/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8ae7840a-2692-457d-b3fd-9d071bea7e12"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC 0187-0901-01</span></p>
<p><span class="Bold"><span class="Italics">Rx Only</span></span></p>
<p><span class="Bold">Testred<span class="Sup">Â®</span> C-III</span><br>(methylTESTOSTERone capsules, USP)</p>
<p><span class="Italics">Each capsule</span><br><span class="Italics">contains</span><br><span class="Italics">10 mg</span><br><span class="Italics">methylTESTOSTERone,</span><br><span class="Italics">USP</span></p>
<p><span class="Bold">10 mg</span></p>
<p><span class="Bold">100</span><br><span class="Bold">Capsules</span></p>
<p>VALEANT<span class="Sup">â„¢</span></p>
<div class="Figure">
<a name="id626"></a><img alt="Principal Display Panel - 10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09db5a9d-9662-4bfb-824c-9c9aaad488dc&amp;name=testred-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TESTREDÂ 		
					C-III</strong><br><span class="contentTableReg">methyltestosterone capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0901</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLTESTOSTERONE</strong> (METHYLTESTOSTERONE) </td>
<td class="formItem">METHYLTESTOSTERONE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VRX;0901</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0901-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA083976</td>
<td class="formItem">12/03/1973</td>
<td class="formItem">01/01/2017</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b012e159-68d9-4fb5-924f-ff50594149c5</div>
<div>Set id: 09db5a9d-9662-4bfb-824c-9c9aaad488dc</div>
<div>Version: 4</div>
<div>Effective Time: 20150401</div>
</div>
</div>Â <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
